# Eli Lilly & Co.

Type: Company (LLY)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/eli-lilly-co
Canonical HTML page: https://getbiobrief.com/entity/eli-lilly-co

## Recent coverage (1 stories)

### CareDx +35% on Medicare Win; Atai +33% on $3.8B Lilly Deal
2026-08-05 07:28:34 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

CareDx surged 35% after Medicare finalized coverage for transplant rejection tests, unlocking a major revenue opportunity. AtaiBeckley soared 33% following Eli Lilly's $3.8B acquisition, while Abbott raised its outlook and Apollomics extended its weekly rally to over 60% on its cancer drug candidate.
Full story: https://getbiobrief.com/story/caredx-atai-abbott-biotech-gainers-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.